by Andrii Buvailo, PhD
This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a …
Read More
by Louise von Stechow
An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting …
Read More
by Andrii Buvailo, PhD
Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra. OpenAI president, Greg …
Read More
by Louise von Stechow, Sudhakaran Prabakaran, PhD
Drug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can manipulate biology. …
Read More
by Louise von Stechow, Marco Lolaico
Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …
Read More
by Andrii Buvailo, PhD
I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions …
Read More
